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[57] ABSTRACT 
Transgenic mice that express increased levels of nerve 
growth factor (NGF) in the epidermis and other strati?ed, 
keratinized epithelium. The nerve growth factor expressing 
transgenic mice are useful in the study of neurodegenerative 
disorders of the brain such as Parkinson’s syndrome and 
Alzheimer’s disease and for testing for drug candidates for 
the treatment of these diseases. 
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TRANSGENIC MICE WHICH 
OVEREXPRESS NERVE GROWTH FACTOR 
This application is a continuation of application Ser. No. 
08/131,424 ?led Oct. 4, 1993, now abandoned. 
TECHNICAL FIELD 
The present invention relates to transgenic mice that 
express increased levels of nerve growth factor (NGF) in the 
epidermis and other strati?ed, keratinized epithelium. The 
nerve growth factor expressing transgenic mice of the 
present invention are valuable to researchers that study the 
role of nerve growth factor and other neurotrophic factors in 
the development and function of the nervous system, and in 
the study of neurodegenerative disorders of the brain such as 
Parkinson’s syndrome and Alzheimer’s disease. 
BACKGROUND 
The survival of developing vertebrate neurons is thought 
to be dependent on access to a limited supply of target 
derived neurotrophic factors. Nerve growth factor (NGF) is 
the most extensively characterized of these factors and has 
been shown to regulate the survival of discrete populations 
of neurons. 
U.S. Pat. No. 4,185,095 to Young discloses the isolation 
of a nerve growth factor from mouse submandibular or 
salivary gland. 
U.S. Pat. No. 5,082,774 to Heinrich discloses a recom 
binant human nerve growth factor. The nerve growth factor 
is in an expression vector with an adenovirus strong, major, 
late promoter. Heinrich discloses that the expression vector 
may be used to stably transfect mammalian cells such as 
CHO or COS cells. 
U.S. Pat. No. 5,180,820 to Barde et al. discloses that NGF 
has been molecularly cloned. 
Various transgenic mice have been patented. U.S. Pat. No. 
4,736,866 to Leder et al. discloses a transgenic non~human 
eukaryotic animal whose germ cells and somatic cells con 
tain an activated oncogene sequence introduced into the 
animal or an ancestor of the animal at an embryonic stage. 
The embryo of the mice were rnicroinjected with approxi 
mately 500 copies of the RSVS-107 c-myc plasmid. The 
injected eggs were transferred to pseudopregnant foster 
families and allowed to develop to term. The plasmid 
contains a Rous Sarcoma Virus enhancer and promoter 
sequence. The resultant mice showed expression of the 
c-myc gene in the salivary gland, spleen, testes, lung, brain, 
and preputial gland and intestinal tissue. 
U.S. Pat. No. 5,175,383 to Leder et al. discloses a male 
transgenic mouse containing germ cells and somatic cells 
which contain a recombinant gene which is a vertebrate gene 
in the Int-2/FGF family which is capable of promoting 
benign prostatic hyperplasia or hypertrophy. The fusion gene 
which is injected into the mouse embryonic tissue comprises 
a promoter sequence controlling transcription of the recom 
binant gene such as a promoter derived from the mouse 
mammary tumor virus and cytomegalovirus. The recombi 
nant gene is preferably substantially homologous with (i.e., 
greater than 50% homologous in terms of encoded amino 
acid sequence) a naturally occurring, vertebrate gene in the 
Int-2/FGF gene family of murine growth factor encoding 
genes or their vertebrate counterparts, including the murine 
acidic or basic ?broblast growth factor genes, the murine 
FGF-S gene, the murine epidermal growth factor gene, the 
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2 
murine insulin-like growth factor-1 and -2 gene, the murine 
ot-transforming growth factor gene with a murine hst/KS3 
gene. The transgenic mice of Leder et al. exhibit prostate 
hyperplasia and give sterile o?fspring. 
U.S. Pat. No. 5,175,384 to Krimpenfort et al. discloses 
transgenic mice having a phenotype characterized by the 
substantial absence of mature T-lymphocytes. The mouse is 
produced by introducing a transgene into a zygote of a 
mouse which comprises gene fragment which encodes a 
T-cell antigen receptor polypeptide variant which is inca 
pable of mediating T-cell maturation in the transgenic 
mouse. 
U.S. Pat. No. 5,175,385 to Wagner et al. discloses the 
production of a transgenic mouse with enhanced viral resis 
tance which is transmissible to its o?°spring. The transgenic 
mouse is prepared by introduction of a gene encoding a 
human interferon having anti-viral activity into a host 
mouse. The plasmid of Wagner et al. contains a methal— 
lothionein-l promoter and the genomic human beta inter 
feron gene. When these mice were injected with pseudora~ 
bies virus they showed an increased resistance to the virus 
and although many mice died they died considerably later 
than did the control animals. 
Vassar et al., in the Proceedings of the National Academy 
of Sciences, Volume 86, pages 1563-1567, March 1989, 
disclose ‘Tissue-speci?c and Dilferentiation-speci?c 
Expression of a Human K14 Keratin Gene in Transgenic 
Mice”. This publication discloses that Vassar et al. used a 
plasmid containing a K14 keratin promoter and a neuropep~ 
tide substance P and determined the expression of the 
plasmid and neuropeptide substance P in the tail skin of 
transgenic mice. 
Vassar et al. in Gene & Development, Volume 5,. pages 
714-727, (1991) disclose “Transgenic Mice Provide New 
Insights into the Role of TGF~(X During Epidermal Devel 
opment and Differentiation”. This publication discloses the 
construction of transgenic mice using a plasmid which 
contains the K14 keratin promoter and the TGF-ot gene. 
Vassar et al. disclose that the TGF-Ot gene belongs to the 
epidermal growth factor family of proteins and shows struc 
tural homology with the epidermal growth factor. These 
transgenic mice showed gross phenotypic abnormalities in 
their skin including ?aky outer epidermal layers with stunted 
hair growth and wrinkling. The plasmid used to create this 
transgenic mouse also included human growth hormone 
fusion gene. 
Patil et al. in Neuron, Volume 2, pages 347-447, March 
1990, disclose “Speci?c Neuronal Expression of Human 
Nerve Growth Factor Receptors in the Basal Forebrain and 
Cerebellum of Transgenic Mice”. Patil et al. employed a 
cosrnid clone containing the entire NGF receptor gene. 
Introduction of the human NGF receptor gene into the 
mouse germ line resulted in signi?cant levels of expression 
in speci?c cells in both the peripheral and central nervous 
systems. The NGF receptor gene and the NGF gene are 
distinct genetic material. 
Borrelli et al. in Proceedings of the National Academy of 
Science, Volume 89, pages 2764-2768, April 1992, disclose 
“Pituitary Hyperplasia Induced by Ectopic Expression of 
Nerve Growth Factor”. Borrelli et al. fused nerve growth 
factor cDNA to rat prolactin promoter to induce its ectopic 
expression in pituitary lactotrophs of transgenic mice. 
Federoif et al. in Proceedings of the National Academy of 
Science, USA, Volume 89, pages 1636-1640, March 1992, 
disclose “Expression of Nerve Growth Factor in Vivo from 
a Defective Herpes Simplex Virus~1 Vector Prevents Effects 
v 
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of Axotomy on Sympathetic Ganglia”. This publication 
teaches that rat nerve growth factor packaged into a herpes 
simplex virus-l particle after axotomy of sympathetic supe 
rior cervical ganglion prevented a decline in the tyrosine 
hydroxylase level which is generally required for mainte 
nance of the noradrenergic neurotransmitter system. 
Edwards et al. in the Cell, Volume 58, pages 151-170, Jul. 
14, 1989, disclose “Directed Expression of NGF to Pancre 
atic B Cells in Transgenic Mice Leads to Selective Hyperin 
nervation of the Islets”. Edwards et al. showed a selective 
increase the expression of NGF in pancreatic [3 cells by 
creating a hybrid gene that contained a rat insulin promoter 
fused to mouse NGF cDNA followed by an intron and 
transcriptional terminator from the SV40 virus. 
PCT Publication WO 93/00909 is directed to a method of 
treating neurotrophin-expressing tumors by administering a 
sequence complementary to at least a portion of a RNA 
transcript of brain-derived neurotrophic factor gene. 
During development of the vertebrate nervous system up 
to half of all neurons generated undergo a process of 
naturally occurring cell death (See Ard, M. D., Morest, D. K. 
(1984). Cell death during development of the cochlear and 
vestibular ganglia of the chick. Intl. J. Dev. Neurosci. 2, 
535-547; and Oppenheim, R. W. (1991). Cell death during 
development of the nervous system. Ann. Rev. Neurosci. 14, 
453-501). 
Neuronal death typically occurs shortly after neurons 
being making functional connections within their target 
?eld. Survival during this period of innervation is thought to 
be dependent on the synthesis by the target tissue of a 
limited quantity of neurotropic substances. (See Thoenen, H. 
and Barde, Y. A. (1980). Physiology of nerve growth factor. 
Physiol. Rev. 60, 1284-1334; Oppenheim, R. W. (1989). The 
neurotrophic theory and naturally occurring motoneuron 
death. Trends in Neurosci. 12, 252-255; and Davies, A. M., 
Larmet, Y., Wright, E., Vogel, K. S. (1991). Coordination of 
trophic interactions by separate developmental programs in 
sensory neurons and their target ?elds. J. Cell Sci. 15, 
111-116)). 
The competition for- target ?eld-derived neurotrophic 
factors is though to serve at least two functions: to ensure 
that an appropriate number of synaptic contacts are made at 
the target and to eliminate inappropriate neuronal projec 
tions. (See Oppenheim, R. W. (1981). Neuronal death and 
some related phenomena during neurogenesis. In Studies in 
Developmental Biology (ed. W. M. Cowan) p 74-133. 
Oxford University Press; and Cowan, W. M., Fawcett, J. W., 
O’Leary, D.D.M., and Stan?eld, B. B. (1984). Regressive 
events in neurogenesis. Science 225, 1258-1265)). 
This concept is referred to as the neurotrophic hypothesis 
and predicts that the number of neurons in the adult could be 
increased if a higher concentration of neurotrophic factor(s) 
was available during the critical time when synaptic contacts 
are being established. 
Nerve growth factor (NGF) is a prototypical target-de 
rived neurotrophic substance that has been shown to be 
essential for the survival and differentiation of neural crest 
derived sensory neurons, sympathetic neurons, and fore 
brain cholinergic neurons. (See Levi-Montalcini, R. and 
Booker B. (1960). Destruction of the sympathetic ganglia in 
mammals by an antiserum to a nerve-growth protein. Proc. 
Natl. Acad. Sci. USA 46, 384-391 and Hefti, F. (1986) J. 
Neurosci. 6, 2155-2161; Williams, L. R., Varon, S., Peter 
son, 6., Wictorin, K., Fischer, W., Bjorklund, A. & Gage, F. 
H. (1986). Proc. Natl. Aced. Sci. U.S.A. 83, 9231-9235). 
The role of NGF in neuron survival is supported by 
numerous studies that have utilized both tissue culture and 
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in vivo approaches in which NGF peptide or NGF antibodies 
were applied. (See Levi-Montalcini and Booker, 1960, 
supra; Johnson, E. M., Gorin, P. D., Brandeis, L. D., Pear 
son, J. (1980). Dorsal root ganglion neurons are destroyed 
by exposure in utero to maternal antibody to nerve growth 
factor. Science 210, 916-918; Barde, Y. A., Edgar, D., 
Thoenen H. (1980). Sensory neurons in culture: Changing 
requirements for survival factors during embryonic devel 
opment. Proc. Natl. Acad. Sci. U.S.A. 77, (1980) 1199-1203; 
Hamburger, V. and Yip, H. W. (1984). Reduction of experi 
mentally induced neuronal death in spinal ganglia of the 
chick embryo by nerve growth factor. J. Neurosci. 4, 
767-774). Sympathetic and certain sensory neurons can be 
reduced by exogenous NGF whereas anti-NGF antibodies 
eliminate these neurons. 
During development of skin, NGF is expressed by target 
cells of the presumptive epidermis and dermis. (See Davies, 
A. M., Bandtlow, D., Heumann, R., Korsching, S., Rohrer, 
H., and Thoenen, H. (1987). Timing and site of nerve growth 
factor synthesis in developing skin in relation to innervation 
and expression of the receptor. Nature 326, 353-358). 
Target-?eld synthesis of N GF coincides with the arrival of 
axons to the epidermis, though the onset of expression as 
well as the concentration of NGF are independent of inner 
vation. (See Rohrer, H., Heumann, R., Thoenen, H. (1988). 
Synthesis of nerve growth factor (NGF) in developing skin 
is independent of innervation. Dev. Biol. 128, 240-244; and 
Harper, S. .l., and Davies, A. M. (1990). NGF mRNA 
expression in developing cutaneous epithelium related to 
innervation density. Development 110,515-519). Thus, cells 
of the target ?eld appear to control the onset and level of 
NGF gene expression. 
In mouse whisker pad skin, time course studies of inner 
vation have shown that by embryonic day 11 (E11) axons 
have grown out to the skin and NGF mRNA expression has 
begun. (See Davies et al., 1987, supra). NGF continues to 
rise until E14 and then falls sharply by E15. The decrease in 
NGF concentration coincides with the onset of death of 
nearly half of the neurons in the trigerninal ganglion. 
As skin innervation proceeds, the embryonic epithelium 
begins the transformation from a two-cell layer, undifferen 
tiated periderm to a multilayer, strati?ed epidermis. (See 
Schweizer, J ., and Winter, H. (1982). Keratin polypeptide 
analysis in fetal and in terminally differentiating newborn 
mouse epidermis. Di?erentiation 22, 19-24; and Kopan, R. 
and Fuchs, E. (1989). A new look into an old problem: 
Keratins as tools to investigate determination, morphogen 
esis, and differentiation in skin. Genes and Devel. 3, 1-15). 
The differentiation of the epidermis is marked by the 
expression of epidermal speci?c genes, one of the earliest 
being the gene encoding the keratin intermediate ?lament 
protein K14. The onset of K14 gene expression in mouse 
skin occurs at approximately E14-E15 (see FIG. 1(b), begin 
ning as NGF concentration is declining. 
Heretofore there has been no convenient method to inves 
tigate how target-derived NGF affects neuron survival and 
development of the peripheral nervous system or provide a 
practical model for testing drug candidates for the treatment 
of neurodegenerative disorders of the brain such as Parkin 
son’s syndrome and Alzheimer’s disease. 
The present invention overcomes the de?ciency by pro 
viding transgenic mice that manufacture increased levels of 
NGF in the basal keratinocytes of the skin and exhibit 
hyperinnervation. 
DISCLOSURE OF THE INVENTION 
The invention provides a transgenic mouse whose somatic 
and germ cells contain and express a gene encoding for 
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nerve growth factor. The gene exhibits hyperinnervation in 
the mouse, and has been introduced into a mouse or an 
ancestor of the mouse at an embryonic stage. The NGF gene 
is operatively linked to a human K14 keratin promoter and 
enhancer region. 
The invention also provides for a mouse wherein the NGF 
gene has been introduced into an ancestor if said mouse at 
an embryonic stage by microinjection. 
In an additional embodiment, the mouse nerve growth 
factor is further operatively linked to the human growth 
hormone gene. 
The invention provides for a mouse which has a pheno 
type characterized by hyperinnervation of the skin, hyper 
trophy of trigeminal ganglion and enlargement of the supe 
rior cervical sympathetic and dorsal root ganglia. 
Advantageously, the present invention provides a method 
of producing the transgenic mouse which overexpresses 
nerve growth factor which comprises 
(a) providing a mouse nerve growth factor gene opera 
tively linked to a human K14 keratin promoter and enhancer 
region functional in said mouse; 
(b) introducing said gene into a mouse embryo; 
(c) transplanting said embryo into a pseudopregnant 
mouse; and 
(d) allowing said embryo to develop to term. 
Furthermore, the invention provides a method of testing 
the ef?cacy of drugs in treating neurodegenerative disorders 
comprising administering said drug to a mouse according to 
the invention, and determining the behavioral effects and 
tissue changes of said drug on said mouse. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. 1a, b, 0: (FIG. 1(a) shows the K14-NGF fusion 
gene contains the mouse NGF cDNA cloned downstream 
from the human epidermal K14 gene promoter and enhancer 
sequences. 
FIG. 1(b) shows a schematic depicting the onset of NGF 
expression by E11, and its rise and fall at E15. 
FIG. 1(0) shows mice screened for the transgene by 
Southern hybridization of DNA isolated from tail samples 
obtained three to four weeks after birth. Blots were probed 
using a 32P-labeled DNA sequence complementary to the 
mouse NGF cDNA. 
FIGS. 2a, b: FIG. 2(a) examines the expression level of 
the K14-NGF transgene for transgenic mouse lines. Shown 
is a 3 d exposure, FIG. 2(a) and a 10 d exposure, FIG. 2(b), 
of the same ?lter. FIG. 2(b) examines the tissue speci?city 
of K14-NGF expression. 
FIGS. 3a-d: FIG. 3 shows cellular expression of the 
K14-NGF transgene in skin from A-56 F1 transgenics was 
examined by in situ hybridization. Basal cells (arrows) in 
whisker pad epidermis, FIG. 3(a), and vibrissa, FIG. 3(0), of 
control animals had silver grain density at background 
levels. A-56 Fl transgenic mice had a greater labeling 
density of whisker pad basal cells, FIG. 3(b) (arrows), and 
vibrissa, FIG. 3(d). 
FIG. 4 shows expression of K14-NGF causes hyperinner~ 
vation of skin. Skin from dorsum, (FIGS. 4a and 4b) and 
whisker pad (FIG. 40 and 4d) was processed for paraffin 
histology and sections stained with hematoxylin and eosin. 
Control skin (FIG. 4a and 40) show few apparent neuron 
bundles whereas A-56 Fl transgenic skin (FIG. 4b and 4d) 
shows numerous, enlarged ?ber bundles. 
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FIGS. 5a—d: FIG. 5 shows immunolabeling of transgenic 
skin reveals a hyperinnervation of sensory and sympathetic 
neurons. To verify that the ?ber bundles in the skin were 
composed of neuronal processes, frozen sections of whisker 
pad skin from control (FIG. 5a) and A-56 Fl transgenics 
(FIG. 5b) were immunolabeled with an anti-neuro?lament 
150 antibody followed by incubation with a goat anti-rabbit 
FITC conjugated secondary. A signi?cant increase in the 
number of ?bers and bundles was seen in an equivalent 
region of A56 transgenic skin (FIG. 5b). A-56 skin con 
tained sympathetic ?bers, sections were immunolabeled 
with an anti-TH antibody followed by a biotinylated goat 
anti rabbit secondary processing with DAB (FIG. Sc). A-56 
F1 transgenics labeled with anti-CGRP followed by a bioti 
nylated goat-anti rabbit secondary antibody are shown in 
FIG. 50!. 
FIGS. 6a, b: FIG. 6 shows expression of K14-NGF causes 
enlargement of the trigeminal and superior cervical ganglia. 
Trigeminal ganglia (FIG. 6a) and superior cervical ganglia 
(FIG. 6b) were removed from control A~48 F1, and A-56 Fl 
mice. 
STATEMENT OF DEPOSIT 
The plasmid containing k14-NGF-hGH has been depos 
ited with the American Type Culture Collection under the 
terms of the Budapest Treaty and is available as Accession 
No. 69423. 
DESCRIPTION OF THE INVENTION 
The present invention provides transgenic mice that 
manufacture increased levels of nerve growth factor (NGF) 
in the basal keratinocytes of the skin. 
The mice are obtained by making a fusion gene construct 
in which the human K14 keratin promoter and enhancer 
region was linked to mouse NGF cDNA. 
To increase the expression of the transgene, a region from 
the human growth hormone gene may, in a preferred 
embodiment, be added to the construct. Production of nerve 
growth factor in the epidermis of these mice was found to 
result in a profound hyperinnervation of the peripheral 
nervous system, i.e. skin has increased nerve ?bers, the 
trigeminal sensory, the superior cervical sympathetic, and 
the dorsal root ganglia were markedly enlarged. 
The nerve growth factor expressing transgenic mice of the 
present invention are valuable to researchers that study the 
role of nerve growth factor and other neurotrophic factors in 
the development and function of the nervous system, and in 
the study of neurodegenerative disorders of the brain such as 
Parkinson’s syndrome and Alzheimer’s disease. 
To investigate the role of NGF in the development of the 
peripheral nervous system and skin innervation, the human 
K14 gene promoter was used to drive the expression of the 
NGF cDNA in basal keratinocytes. Results show that target 
derived overexpression of N GF has profound effects on the 
level of skin innervation and neuronal survival. 
Below is a more detailed outline of experimental proce 
dure. NGF cDNA was linked to the promoter and enhancer 
regulatory regions of the human keratin 14 gene. The 
K14-NGF fusion gene was expressed at approximately 
embryonic day 14, the time at which endogenous NGF 
levels begin to decline and programmed neuronal death 
begins. In situ hybridization of skin of K14-NGF transgenics 
had increased levels of NGF mRNA in the basal cells of the 
epidermis and associated hair follicle structures. The 
5,602,309 
7 
increase in target derived NGF mRNA was correlated with 
a hypertrophy of peripheral sensory and sympathetic nerves, 
hyperinnervation of the skin, and a 26-1 17% increase in the 
number of primary sensory neurons in the trigeminal gan 
glion. 4 
These results demonstrate that the level of NGF produc 
tion by the target tissue dictates the level of neuron survival, 
and in so doing, in?uences the distribution and number of 
neurons in the adult. 
Expression of K14-NGF in Skin of Transgenic 
Mice 
NGF was overexpressed in the epidermis of transgenic 
mice using a fusion gene construct in which the human 
epidermal K14 keratin promoter and enhancer sequences 
were linked to a mouse NGF cDNA (FIG. 1a). The K14 
promoter has previously been shown to direct high level of 
expression of various transgenes to basal keratinocytes of 
the epidermis. (See Vassar, R., Rosenberg, M., Ross, 8., 
Tyner, A. & Fuchs, E. (1989). Tissue-speci?c and differen 
tiation-speci?c expression of a human K14 keratin gene in 
transgenic mice. Proc. Natl. Acad. Sci. 86, 1563-1567; and 
Vassar, R., Coulombe, P. A., Degenstein, L., Albers, K. & E. 
Fuchs (1991). Mutant keratin expression in transgenic mice 
causes marked abnormalities resembling a human genetic 
skin disease. Cell 64, 365—380). 
The rationale in designing the K14-NGF construct is 
based on the temporal overlap of NGF down-regulation with 
the initiation of K14 expression, i.e., as the concentration of 
target derived NGF beings to fall and neuronal cell death 
commences (El4-El5, see FIG. 1(b)), the K14-NGF trans 
gene turns on, producing elevated levels of NGF during the 
critical period of cell death and thereafter in the adult (FIG. 
112). 
Three founder mice have been isolated that express the 
transgene (FIG. 10). Founder A-39 (FIG. 1c, lane 1) and 
founder A-56 (lane 3) were smaller and exhibited a lower 
rate of weight gain when compared to their nontransgenic 
siblings, whereas founder A-48 was normal in size. Fl 
oifspring of founder A-56 also exhibited reduced weight 
gain. Founder A-39 has not generated transgenic offspring, 
though approximately eighty offspring have been screened. 
The A-56 transgenics also had delayed eye opening (at least 
2-3 days later than nontransgenic siblings) and frequently 
exhibited a “squinty” appearance. This phenotype does not 
appear to be due to an increase in light sensitivity since even 
under low level lighting they retained a squinting appear 
ance. 
The relative level of K14~NGF expression in the three 
founders was determined using Northern hybridization 
analysis of total RNA isolated from full thickness skin (FIG. 
2). Nontransgenic control skin samples (FIG. 2, lane 1) had 
a single faint band hybridizing with the radiolabeled NGF 
probe at approximately 1.3 kb, a size corresponding to the 
endogenous RNA transcript. 
RNA samples isolated from the A-39 (lane 2), A48 (lane 
3), and A-56 (lane 4) skin contained, in addition to the 
endogenous transcript, a 1.9-kb band that corresponded to 
the predicted size of the K14-NGF transcript. Line A-39 and 
A-48 had comparable levels of transgene expression 
whereas expression in the A-56 line was signi?cantly higher. 
Previous studies using the K14 promoter and enhancer 
region to express other transgenes of interest have shown 
transgene expression restricted to stratified, keratinized tis 
sues such as skin, tongue, esophagus, and forestomach. 
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To verify that the tissue distribution of K14-NGF expres 
sion was comparable, RNA was analyzed from tongue, 
brain, heart, liver, and kidney of an A-56 Fl transgenic and 
nontransgenic control. Expression of the K14-NGF trans 
gene was restricted to the keratinized epithelium samples 
examined, skin (FIG. 2, lane 5) and tongue (lane 6). The 
endogenous NGF transcript was detectable in skin (lanes 5 
and 11), tongue (lanes 6 and 12), brain (lanes 7 and 13), heart 
(lanes 8 and 14), and kidney (lanes 10 and 16) of both the 
control and transgenic tissues. Liver tissues (lanes 9 and 15) 
showed no evidence of NGF expression. 
Cellular expression of the K14-NGF transgene was exam 
ined using in situ hybridization on sections of whisker pad 
skin, a region known to have a high level of innervation 
(FIG. 3). A 35S-labeled cRNA probe speci?c for the mouse 
NGF mRNA was hybridized to skin sections of 4 week-old 
K14-NGF transgenics and non-transgenic siblings and pro 
cessed for autoradiography. Few autoradiographic grains 
were observed in the control skin (FIG. 3a) whereas the 
K14-NGF skin showed dense hybridization in the epidermal 
basal cell layer with decreasing intensity in suprabasal layers 
(FIG. 3b). Dense hybridization was also found in epidermal 
cells of the outer root sheath of hair and vibrissa follicles of 
transgenic mice (FIG. 3d), but not in the corresponding areas 
of nontransgenic (FIG. 30). The epidermal and hair follicle 
distribution of hybridization is consistent with the known 
expression pattern of the K14 keratin (Schweizer and Win 
ter, 1982; Kopan and Fuchs, 1989). 
Histological Examination of NGF Levels 
To determine whether the increased level of N GF mRNA 
in the transgenic epidermis was processed into functional 
NGF peptide, the skin of the transgenics was examined for 
evidence of increased neuronal survival. Histological exami 
nation of skin from various regions of the body (dorsum, 
ventral, tail, ear locations) revealed an increase in nerve 
processes and an abundance of large nerve bundles coursing 
throughout the papillary and reticular layers of the dermis 
(FIG. 4a, control; 4b, transgenic). 
To con?rm that these structures were composed of neu 
ronal processes, whisker pad skin from A-56 Fl mice was 
immunolabeled with an antibody directed against the 150 
Kd neuro?lament protein (FIG. 4c, control; 4d, transgenic). 
In control mice, neuro?lament positive ?bers and bundles 
were evident in the reticular and deep layers of the dermis. 
Occasional small positive ?bers could also be found pen 
etrating the lower layers of the epidermis and in association 
with hair follicle and vibrissa structures. 
A striking increase in the density and size of neuronal 
processes was apparent in skin of A-56 transgenics (FIG. 
4d). Hyperinnervation was clearly evident in the papillary 
and reticular layers of the dermis as well as around hair 
follicle structures. Hyperinnervation was also apparent in 
skin of A-48 Fl mice, though at a reduced level than in the 
A-56 transgenics. 
Two primary sources of axons for the observed whisker 
pad hyperinnervation are sensory neurons originating in the 
trigerninal ganglion and sympathetic postganglionic ?bers 
arising from the superior cervical ganglion. As a ?rst step in 
determining the contribution from these two sources, immu 
nocytochemistry was performed using antibodies directed 
against the neurotransmitter calcitonin gene related peptide 
(CGRP), for identi?cation of sensory neurons and the cat 
echolamine-synthesizing enzyme tyrosine hydroxylase 
(TH), for identi?cation of postganglionic sympathetic 
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axons. (See Gibbins, I. L., Fumess, J. B., Costa, M., Macln~ 
tyre, I., Hillyard, C. J. and Girgis, S. (1985). Colocalization 
of calcitonin gene-related peptide-like immunoreactivity 
with substance P in cutaneous, vascular and visceral sensory 
neurons of guinea pigs. Neurosci. Lett. 57, 125-130). 
CGRP is enriched in sensory nerves projecting to hair 
follicles and as free endings in the epidermis. (See Kruger, 
L. Silverman J. D., Mantyh P. W., Stemini, C., Brecha, N. C. 
(1989). Peripheral patterns of calcitonin gene-related pep 
tide general somatic sensory innervation: cutaneous and 
deep terminations. J. Comp. Neurol. 280, 291-302; and 
Shotzinger, R. J ., and Landis, S. C. (1990). Postnatal devel~ 
opment of autononric and sensory innervation of thoracic 
hairy skin in the rat. Cell Tissue Res. 260, 575-587). 
Though CGRP staining has been reported in sympathetic 
ganglion, it is thought to represent afferent input, not CGRP 
production by ganglionic neurons. In control skin (FIG. 5a), 
few CGRP-positive ?bers could be identi?ed. In contrast, 
the K14-NGF transgenic skin had numerous small and large 
bundles of CGRP-labeled ?bers throughout the dermis, 
particularly in regions beneath the epidermis where abun 
dant axons terminations occur (FIG. 5b). 
Sympathetic innervation of transgenic skin was enhanced 
as shown by an increase in TH-immunoreactive ?bers (FIG. 
6c, control; 6d, transgenic). Much of the increased TH 
labeling was on ?ber bundles in the upper regions of the 
dermis that also labeled for CGRP. TH-positive ?bers 
appeared different from CGRP positive ?bers however, in 
being thin, with numerous swellings. CGRP ?bers were 
thicker and more uniform. Further distinction between 
CGRP labeled and TH labeled ?bers was found in exami 
nation of Merkel cells of vibrissa structures. (See Nurse, C. 
A., Mearow, K. M., Homes, M., Visheau, B., and Diamond, 
J. (1983). Merkel cell distribution in the epidermis as 
determined by quinacrine fluorescence. Cell Tissue Res. 228, 
51-54). Sensory, but not sympathetic neurons, recognize 
and associate with Merkel cells. (See Vos, R, Stark, E, and 
Pittman, R. N. (1991). Merkel cells in vitro: Production of 
nerve growth factor and selective interactions with sensory 
neurons. Dev. Biol. 144, 281-300). In transgenic and control 
samples only CGRP labeled ?bers could be found associated 
with Merkel cells of the whisker follicle whereas no TH 
labeling was evident. 
It was found that TH and CGRP synthesis is enhanced by 
NGF. No di?ference in TH-labeling could be discerned 
between the control and transgenic samples in the deep 
dermis. Few TH-immunoreactive ?bers could be found in 
the deep dermis and these ?bers were frequently associated 
with blood vessels that were adjacent to the underlying 
muscle layer, a location consistent with their sympathetic 
nature. 
It was also found that NGF induces hypertrophy of 
trigenrinal ganglion. The availability of elevated NGF pep~ 
tide to neurons in the epidermal target ?eld of the transgen~ 
ics was further indicated by a striking hypertrophy of the 
trigerrrinal ganglion and the branches emanating from it. 
Cell counts made of ganglia isolated from three A-56 F1 
transgenics had values that ranged from 26 to 117% greater 
than nontransgenic age-matched controls (Table 1 below). 
The hypertrophy of the trigenrinal ganglion was also 
reflected by the enlargement of the primary branches of the 
trigeminal nerves. In the maxillary division of the trigeminal 
nerve dissected from control and transgenic samples, the 
transgenic nerve bundle (branch) is clearly larger than the 
control. 
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TABLE 1 
Number of Percent 
Case Number Age Neurons Difference 
0401 Non-transgenic 24 d 26,054 55 
0401 K14-NGF transgenic 24 (1 40,285 
0527 Non-transgenic 29 d 26,493 117 
0527 K14-NGF transgenic 29 d 57,767 
0513 Non-transgenic 36 d 28,867 26 
0513 Kl4-NGF transgenic 36 d 36,562 
A transgenic mouse model system was used to study the 
role of target ?eld-derived NGF in development of the 
peripheral nervous system. Elevation of the production of 
NGF by the epidermal target tissue caused a dramatic 
increase in neuronal survival as evidenced by a striking 
hyperinnervation of the skin and hypertrophy of the trigemi 
nal ganglia. Both sensory and sympathetic neurons in the 
transgenic skin appeared to be rescued by the increased NGF 
production as evidenced by enhanced CGRP- and TH 
immunoreactivity. That both sensory and sympathetic neu 
ron populations had increased survival is consistent with the 
known dependence of these cells on NGF. Sensory neurons 
are most dependent during embryonic development (shortly 
before birth) whereas sympathetic neurons require NGF 
within a 304 week period after birth. (See Levi~Montalcini 
and Booker, 1960, supra; Johnson et a1., 1980, supra). 
Since expression of the Kl4-NGF transgene begins at 
E14-E15, rises, and continues at a steady level in the adult, 
both sensory and sympathetic neurons would be exposed to 
elevated NGF at critical times in their development. Nerve 
terminals of both sympathetic and sensory neurons would 
presumably have access to a greater amount of NGF pro~ 
duced by the transgenic epidermis and transport it from the 
skin to cell bodies. Both sensory and sympathetic nerves 
have been shown to take up labeled NGF and transport it 
retrogradely. (See Hamburger, V., Brunso-Bechtold, J. K., 
Yip, J. W. (1981). Neuronal death in the spinal ganglia of the 
chick embryo and its reduction by nerve growth factor. J. 
Neurosci. 1, 60-71; and Stockel, L., Schwab, M. E., Thoe 
nen, H. (1975). Comparison between the retrograde axorral 
transport of nerve growth factor and tetanus toxin in motor, 
sensory and adrenergic neurons. Brain Res. 89, 1-16). 
It was found that TH and CGRP can be upregulated by 
NGF. During normal development, the maximum number of 
cells in the trigeminal ganglia are found at E13 (see FIG. 
1(b). (See Davies, A. M. and A. Lumsden, (1984). Relation 
of target encounter and neuronal death to nerve growth 
factor responsiveness in the developing mouse trigeminal 
ganglion. J. Comp. Neurol. 223, 124-137). These values are 
twice that measured at postnatal day four, a result consistent 
with the neurotrophic theory that up to half of all sensory 
neurons produced during development die as the animal 
matures. The trigeminal ganglia of mice expressing the 
K14-NGF transgene had up to double the number of cells 
than present in control mice. 
Since the addition of exogenous NGF is known to block 
sensory neuron death, the most likely explanation for the 
increased cell number in the transgenic ganglia is that the 
supernormal levels of N GF generated by K14NGF trans gene 
expression in the target prevented cell death. Another pos 
sibility is that additional neurogenesis was induced by 
increased levels of NGF. Recent studies have suggested that 
NGF can act as a rrritogen in the anterior pituitary and as a 
meiotic growth factor during spermatogenesis. (See Borrelli, 
E., Sawchenko, P. D. Evans, R. M. (1992). Pituitary hyper 
plasia induced by ectopic expression of nerve growth factor. 
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Proc. Natl. Acad. Sci. USA. 89, 2764—2768; and Parvinen, 
M., Pelto-Huikko, M., Soder, 0., Schults, R., Kaipia, A., 
Mali, P., Toppari, J ., Hakovirta, H., Lonnerberg, P., Ritzen, 
E. M., Ebendal, T., Olson, L., Hokfelt, T., Persson, H. 
(1992). Expression of B-nerve growth factor in rat semin— 
iferous epithelium: speci?c function at the onset of meiosis. 
J. Cell Biol. 117, 629-642). 
However, if NGF does exert a mitogenic effect on periph 
eral neurons it must occur prior to the ?rst four-to-six weeks 
of postnatal development (the age at which animals were 
examined), since we observed no mitotic ?gures in the 
trigeminal ganglia despite examination of over 4000 cells/ 
ganglia. In addition, the K14-NGF transgene is active after 
the period of normal cell birth and at a time when sensory 
neurons have completed their migration and extended pro 
cesses into the periphery. Typically, sensory neurons that are 
this highly differentiated do not undergo neurogenesis. (See 
Pannese, E. (1974). Adv. Anat. Cell Biol. 47, 1). 
In addition to the apparent sensory neuron hyperinnerva 
tion, some of the increased innervation resulted from 
increased survival of NGF responsive sympathetic postgan 
glionic neurons that innervate blood vessels, sweat glands, 
and the erector pili muscles associated with hair follicles. 
Sympathetic neuronal cell bodies that innervate the whisker 
pad skin are located in the superior cervical ganglion, a 
structure that was also enlarged in the K14-NGF transgenics. 
The increase in tyrosine hydroxylase irnrnunoreactivity was 
restricted to the ?ber bundles in the super?cial portion of the 
dermis. Blood vessels which normally receive a few 
intensely stained TH-positive ?bers appeared to have the 
same low level of sympathetic innervation in the transgenic 
mice. These blood vessels are well removed from the basal 
keratinocytes expressing the NGF transgene suggesting the 
hyperinnervation is supported only for those structures near 
the site of NGF overproduction. 
The hyperinnervation of a target may be dependent on 
factors other than increased expression of NGF. Merkel cells 
are abundant in vibrissae structures and receive sensory 
input. In the K14-NGF transgenics, a large increase in the 
number of CGRP-positive ?bers projecting to these cells 
was found. No TH~positive ?bers were seen projecting to 
these cells even though large numbers of TH-positive axons 
were seen in nerve bundles immediately adjacent to the 
vibrissae. These results agree with experiments reported by 
Edwards et al. in which the rat insulin promotor was utilized 
to overexpress the NGF cDN A in islet cells of the pancreas. 
(See Edwards, R. H., Rutter, W. J., Hanahan, D. (1989). 
Directed expression of NGF to pancreatic B cells in trans 
genic mice leads to selective hyperinnervation of the islets. 
Cell 58, 161—170). 
Hyperinnervation of the pancreas was observed, though 
the sole source of innervating ?bers appeared to be sympa 
thetic postganglionic neurons. No apparent effect of 
increased NGF was observed on sensory ?bers. From this 
?nding it was proposed that the selective affect on sympa 
thetic axons was due to unidenti?ed cofactors that supported 
hyperinnervation of the sympathetic but not sensory axons. 
This type of mechanism may have relevance to another 
transgenic mouse expression study in which the prolactin 
promotor was utilized to target NGF expression to the 
anterior pituitary, a tissue not normally innervated. Though 
an increased amount of NGF was synthesized, the anterior 
pituitary was not innervated, i.e., NGF did not induce 
innervation of an inappropriate target. 
The expression paradigm used has allowed an examina 
tion of the neurotrophic hypothesis and the eifect of 
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increased target-derived NGF on cell survival. The results 
demonstrate that the increased expression of NGF in the 
developing epidermis can inhibit, if not completely block, 
neuron cell death. Moreover, the increase in the number of 
surviving neurons was independent of changes in the vol 
ume of the skin or number of cells in the target tissue (in this 
case the skin) indicating the trophic factor alone can regulate 
the number of surviving axons. 
These results support the neurotrophic hypothesis and 
speci?cally demonstrate that the skin, by regulating the 
timing and amount of NGF expression independent of 
innervation plays a central role in the development of the 
peripheral nervous system. 
EXAMPLES 
EXAMPLE 1 
Construction of K14-NGF transgene and introduction into 
mice. Plasmid pKS-NGF (a gift from R. Edwards, U.C.L.A.) 
was cut with Apa 1 (+230) and Pst l (+1027) to remove a 
797 base pair fragment that encodes the NGF short transcript 
(Edwards et al., 1989). The overhanging ends of the Apa 
l-Pst l NGF fragment were removed using mung bean 
nuclease and the fragment was gel puri?ed and ligated into 
the BamHl cut, Klenow ?lled K14-hGH cassette vector 
(Vassar and Fuchs, 1991, supra). Dr. Elaine Fuchs (Univer 
sity of Chicago) provided the K14-hGH plasmid. 
K14-hGH contains 2.1 kbp of 5 ' upstream sequence of the 
human K14 keratin gene and a 1.8 kbp intron containing 
sequence from the human growth hormone (hGH) gene. The 
hGH sequence serves to upregulate expression of the trans 
gene and provides a polyadenylation signal. (See Sandgren, 
E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L. & Lee, 
D. C. (1990). Overexpression of TGF alpha in transgenic 
mice: Induction of epithelial hyperplasia, pancreatic meta 
plasia, and carcinoma of the breast. Cell, 61, 1210-1135). 
The S-kbp EcoRl kl4-NGF-hGH fragment (FIG. 1a) was 
isolated on 0.8% Seaplaque agarose gel (FMC Corporation), 
extracted from the gel using glassmilk puri?cation 
(Geneclean Bio 101), and run through a NACS column 
(Bethesda Research Laboratories). 
The plasmid used to transfect mouse cells according to the 
present invention kl4‘NGF-hGH has been deposited with 
the American Type Culture Collection under the terms of the 
Budapest Treaty and is available as Accession No. 69423. 
DNA was ethanol precipitated, resuspended in phosphate 
buffered saline at a concentration of 5 pg/ml, and injected 
into fertilized C3HB6 mouse (Harlan Laboratory Supplies) 
embryos. Injections and implantations were carried out 
using standard procedures. (See Hogan, B., Costantini, F. & 
Lacy, E. (1986). Manipulating the Mouse Embryo: A Labo 
ratory Manual (Cold Spring Harbor Press, Cold Spring 
Harbor, NY.) 
Mice were screened for the transgene using Southern 
hybridization analysis on DNA extracted from tail or by 
employing the polymerase chain reaction on DNA samples 
isolated from ear punches. For Southern hybridizations, 10 
ug of DNA was digested with Pst 1, separated on an 0.7% 
agarose gel, transferred to nitrocellulose by blotting and 
probed with a random primed 32P-dCTP (New England 
Nuclear) labeled probe made to the full length NGF cDNA. 
EXAMPLE 2 
Analysis of mRNA expression by Northern hybridization. 
Northern analysis was performed on RNA that was isolated 
from various tissues using guanidium thiocyanate/ phenol/ 
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chloroform extraction. (See Chomczynski, P. & Sacchi, N. 
(1987). Single-step method of RNA isolation by acid guani 
dinium thiocyanate-phenolchlorofonn extraction. Analyt. 
Biochem. 162, 156-159). 
Fifteen micrograms of total RNA was resolved on a 1.2% 
agarose formaldehyde denaturing gel, transferred to Nytran 
membrane (Schleicher and Schuell) by blotting, baked 2 h in 
a vacuum oven at 80° C., and then hybridized to a 32P-dCTP 
labeled random primed probe made to the full length NGF 
cDNA. ' 
EXAMPLE 3 
In situ hybridization. 35S-labelled cRNA probes were 
generated by adding lug of linearized pKS-NGF plasmid 
(linearized with Sac l for an antisense probe and EcoRl for 
a sense probe) to 2.5mM each ATP, CTP, GTP, 15 mM 
[35S]UTP (New England Nuclear) and either T7 or T3 
polymerase (Stratagene) to generate antisense and sense 
probes, respectively. Incubation was for 60 min at 40° C. in 
transcription buffer containing 50 mM MgCl2, 20 mM 
spermidine, 20 mM Tris (pH 7.4) and 10 mM DTT. The 
solution was phenol1chloroformextracted and precipitated 
with ammonium acetate and 2.5 volumes of ethanol in the 
presence of 25 pg carrier tRNA. 
For in situ hybridization, mouse whisker pad skin was 
dissected, immediately frozen on dry ice, cryostated at 
10-20 pm, mounted onto Vectabond-coated slides (Vector 
Labs) and stored at —80° C. until hybridized. To hybridize, 
slides were brought to room temperature, ?xed for 10 min in 
4% paraformaldehyde, washed in diethyl pyrocarbonate 
(DEPC)-treated phosphate buffer, transferred to 0.25% ace~ 
tic anhydride in 0.1 M TEA (pH 8/0) for 10 min at room 
temperature, dehydrated through a graded series of alcohols 
and defatted in chloroform. Sections were hybridized for 
12-24 hr at 60° C. in a hybridization solution consisting of 
IXIOTM cpm/ml of 35—labeled cRNA probe, 50% formamide, 
1X Denhardt’s solution, 200 mMTris (pH 7.5), 10% dextran 
sulfate, 0.3 ug/ml salmon sperm DNA, 0.15 mg/ml tRNA, 
and 40 mM DTT. Slides were washed in 4><SSC (1XSSC= 
0.15M NaCl, 0015M sodium citrate, pH 7.0), incubated in 
20 mg/ml ribonuclease A (Sigma) dissolved in 10 mM 
Tris-saline, and then washed through descending concentra 
tions of SSC. The ?nal wash was with 0.1><SSC at 37° C. for 
1 hour. Sections were air~dried and placed in X-ray cassettes 
with Hyper?lm B-Max X-ray ?lm (Amersham). Films were 
exposed for 3-7s and developed in Kodak D-l9. Selected 
slides were dipped in Kodak NTB-2 liquid emulsion, air 
dried and exposed to ?lm. Emulsion dipped slides were 
developed in D19, ?xed in Kodak rapid ?xer, counterstained 
with hematoxylin/eosin or cresyl violet and coverslipped in 
Pennount. 
Skin sections from transgenic mice and nontransgenic 
siblings were processed in parallel. Controls for probe 
speci?city included hybridization using a sense cRNA probe 
and pretreatment of tissue with RNase. Both of these con 
ditions resulted in the absence of hybridization. 
EXAMPLE 4 
Cell counts of tn'geminal neurons. Cell counts were 
obtained using the method of Coggelshall et al. (See Cog 
gelshall, R. E., Chung, K., Greenwood, D., Hulsebosch, C. 
(1984). An empirical method for converting nucleolar 
counts to neuronal numbers. J. Neurosci. Methods 12, 
125-132; Coggelshall, R. E., La Forte, R., and Klein, C. M. 
(1990). Calibration of methods for determining numbers of 
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dorsal root ganglion cells. J. Neurosci. Methods 35, 
187-194.). 
This method is based on a determination of the number of 
neuronal nucleoli. Animals were placed under deep anes 
thesia and perfused transcardially with 4% paraformalde 
hyde in 0.1M phosphate buffer, pH 7.4. Trigeminal ganglia 
were removed and immersion ?xed in 4% paraformalde 
hyde, dehydrated in alcohol, defatted and embedded in 
para?in. Entire ganglia were serial sectioned at 6 pm and 
stained with hematoxylin and eosin. Every tenth section was 
examined at a total magni?cation of 400x and a drawing 
tube was used to trace the outline of the section and to 
demarcate the location of each sensory neuron containing a 
nucleoli. To compensate for neurons with two or more 
nucleoli, pro?les of randomly selected neurons were recon 
structed and the total number of nuclei per 100 neurons was 
determined. This provided a ration of nucleoli/neuron that 
was multiplied by the total neurons counted to obtain the 
total number of neurons per ganglion (Coggeshall et al., 
1990, supra). 
EXAMPLE 5 
Immunohistochemistry. Tissue was immersed in ?xative 
for 90 min., transferred to 20—30% sucrose in phosphate 
buffered saline (PBS) and incubated overnight at 4° C. 
Samples were cryostated at 10 pm, thaw-mounted onto 
Vectabond-coated glass slides and processed for immuno 
cytochernistry. 
Sections were incubated with primary antibody (diluted in 
PBS containing 1% normal goat serum and 0.3% Triton 
X-l00), 18-24 h at 4° C. in a humidi?ed chamber, rinsed in 
PBS for 30 min (3 changes), incubated in a secondary 
antisera consisting of appropriate ?uorophore~conjugated 
IgG immunoglobulins (diluted in PGC with 0.3% Triton 
X-100; l h at room temperature), rinsed in PBS, and 
coverslipped. 
Primary antibodies recognizing the following proteins 
were used: anti-150 Kd neuro?lament protein (NE 150; 
1:300 dilution; Chemicon), calcitonin gene related peptide 
(CGRP; 1:200 dilution; Chemicon), tyrosine hydroxylase 
(TH; 1:100 dilution; Chernicon). 
Binding of the neuro?lament antibody was visualized 
using anti-rabbit ?uorocein isothiocyanate conjugated sec 
ondary antibody (Cappel Laboratories). Visualization of 
CGRP and TH irnmunoreactivity was achieved using avidin 
biotin~peroxidase complex (ABC) kit from Vector Labora 
tories. 
After primary antibody incubation, sections were washed 
twice in PBS (5 min. each) incubated in biotinylated goat 
anti rabbit secondary antibody for 30 min., washed in PBS 
and incubated in the ABC complex for 30 min. following 
two PBS Washes, immunoreactivity was visualized by incu 
bation in 0.025% 3,3'—diaminobenzidine-4HC1 (Aldrich) 
with 0.05% H202 and 1.5% nickel ammonium sulfate dis 
solved in 0.1M sodium acetate buffer, pH 6 for 7 minutes. 
EXAMPLE 6 
To test the efficacy of drugs in treating neurodegenerative 
disorders, a drug candidate is administered to a mouse 
according to the invention. The behavioral effects and tissue 
changes of the mouse are determined upon administration of 
the drug. 
DETAILED DESCRIPTION OF THE DRAWINGS 
FIG. 1 Transgene Construct and characterization of trans 
genic expression 
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FIG. 1(a) shows the K14-NGF fusion gene contains the 
mouse NGF cDNA cloned downstream of the human epi 
dermal K14 gene promoter and enhancer sequences (Vassar 
et al., 1989). A fragment containing a partial sequence of the 
hGH gene was ligated downstream of the NGF insert to 
provide an intron containing sequence and poly A (pA) 
addition signal. Arrow indicates transcription start site. FIG. 
1(b) shows a schematic depicting the onset of NGF expres~ 
sion by E11, and its rise and fall at E15. As the endogenous 
level of NGF decreases, expression of the K14-NGF trans 
gene begins, rises to a steady level and continues in the adult 
skin. Actual relative levels of expression are not implied. 
FIG. 1(a) shows mice were screened for the transgene by 
Southern hybridization of DNA isolated from tail samples 
obtained three to four weeks after birth. Blots were probed 
using a 32P-labeled DNA sequence complementary to the 
mouse NGF cDNA. The NGF probe detects both the trans 
gene at 1.8 kbp (arrowhead) and the single copy, endogenous 
NGF gene (1.58 kbp band below the transgene). Three 
founder animals were isolated: Lane 1, A-39; Lane 2, A-47; 
Lane 3, A-56; Lane 4, nontransgenic control. 
FIG. 2 Expression of the K14-NGF transgene is tissue 
speci?c 
FIG. 2(a) examines the expression level of the K14-NGF 
transgene for each line. RNA was isolated from full thick 
ness skin of 4-6 week-old Fl mice and analyzed using 
Northern hybridization. Ten micrograms of total RNA was 
resolved on a formaldehyde denaturing gel, transferred to 
Nytran membrane and probed with a 32P-labeled DNA 
sequence complementary to the NGFrnRNA. All samples 
were loaded onto a single gel. Two ?lm exposure were done 
in order to detect the low level expression of endogenous 
NGF transcript. Shown is a 3 d exposure, FIG. 2(a) and a 10 
d exposure, FIG. 2(b), of the same ?lter. Lane 1, skin RNA 
of nontransgenic control. A faint band is visible at 1.3 kb 
corresponding to the endogenous NGF transcript; lane 2, 
RNA from tail skin of A-39 founder. Transgene mRN A band 
(arrowhead) is apparent at the predicted size of 1.9 kb; lane 
3, skin RNA ofA~47 F1, lane 4, skin RNA ofA-56 Fl, lane 
5, skin RNA of A47 F1 (loaded twice); lane 6, tongue RNA 
of A-56 Fl. Tongue is a keratinized, K14 keratin expressing 
structure expected to have transgene expression. 
FIG. 2(b) examines the tissue speci?city of K14-NGF 
expression. RNA from brain (lane 7, A-56; lane 13, control), 
heart (lane 8, A-56; lane 14, control), liver (lane 9, A-56, 
lane 15, control), and kidney (lane 10, A-56; lane 16, 
control) were tested. Transgene expression was not evident 
in these structures, though the l.3~kb endogenous NGF 
transcript could be detected in all but liver samples. Lane 11, 
control skin RNA; lane 12, control tongue RNA. The 28s 
and 18s ribosomal RNA size markers are indicated by bars 
on right. 
FIG. 3 K14-NGF transgene produces elevated levels of 
NGF mRNA in skin. 
FIG. 3 shows cellular expression of the K14-NGF trans 
gene in skin from A-56 F1 transgenics was examined by in 
situ hybridization. 35S-labeled cRNA sense and antisense 
probes were hybridized to frozen sections of whisker pad 
skin. Basal cells (arrows) in whisker pad epidermis, FIG. 
3(a), and vibrissa, FIG. 3(0), of control animals had silver 
grain density at background levels. A-56 F1 transgenic mice 
had a greater labeling density of whisker pad basal cells, 
FIG. 3(b) (arrows), and vibrissa, FIG. 3(d). Control hybrid 
izations using a sense riproprobe showed background levels 
of hybridization. Bar=50 pm. 
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FIG. 4 Expression of K14-NGF causes hyperinnervation 
of skin. 
Overproduction of NGF by the epidermis caused by 
hyperinnervation that was evident with normal histology. 
Skin from dorsum, (FIGS. 4a and 4b) and whisker pad (FIG. 
4c and 4a’) was processed for para?in histology and sections 
stained with hematoxylin and eosin. Control skin (FIG. 4a 
and 40) had few apparent neuron bundles whereas A-56 Fl 
transgenic skin (FIG. 4b and 4d) showed numerous, 
enlarged ?ber bundles (arrowheads. * =muscle. BaFlO um. 
FIG. 5 Immunolabeling of transgenic skin reveals a 
hyperinnervation of sensory and sympathetic neurons. 
To verify that the ?ber bundles in the skin were composed 
of neuronal processes, frozen sections of whisker pad skin 
from control (FIG. 5a) and A-56 Fl transgenics (FIG. 5b) 
were immunolabeled with an antineuro?lament 150 anti 
body followed by incubation with a goat anti-rabbit FITC 
conjugated secondary. Control skin had immunoreactive 
?bers (arrowheads) in the reticular layer of the dermis, deep 
dermis, and around hair follicles and vibrissa (arrow). A 
signi?cant increase in the number of ?bers and bundles was 
seen in an equivalent region of A-56 transgenic skin (FIG. 
512). To determine whether the large nerve bundles in the 
A-56 skin contained sympathetic ?bers, sections were 
immunolabeled with an anti-TH antibody followed by a 
biotinylated goat-anti rabbit secondary processing with 
DAB (FIG. 5c). TH positive ?bers, which were rare in 
control skin, were found throughout the dermis (arrow 
heads). To examine peripheral sensory ?bers in the trans 
genic skin, A-56 F1 transgenics were labeled with anti 
CGRP followed by a biotinylated goat-anti rabbit secondary 
antibody (FIG. 5d). Large numbers of CGRP positive ?bers 
and nerve bundles were present in the dermis and around 
vibrissa. Inset shows vibrissa surrounded by CGRP positive 
?bers (arrowheads). Bar:5 um. 
FIG. 6 Expression of K14~NGF causes enlargement of the 
trigeminal and superior cervical ganglia. 
Trigeminal ganglia (FIG. 6a) and superior cervical gan 
glia (FIG. 6b) were removed from control A-48 F l, and A-56 
F 1 mice. For both the trigeminal and sympathetic superior 
cervical ganglia, controls (left) were smaller than either the 
A-48 (center) or A-56 ganglia (right. Bar=1 mm). 
The foregoing description of the speci?c embodiments 
will so fully reveal the general nature of the invention that 
others can, by applying current knowledge, readily modify 
and/or adapt for various applications such speci?c embodi 
ments without departing from the generic concept and 
therefore such adaptations are intended to be comprehended 
within the meaning and range of equivalents of the disclosed 
embodiments. It is to be understood that the phraseology or 
terminology employed herein is for the purpose of descrip 
tion only and not of limitation. It is obvious that certain 
changes and modi?cations may be practiced within the 
scope of the appended claims. 
We claim: 
1. A transgenic mouse whose somatic and germ cells 
contain and express a gene encoding for mouse nerve 
growth factor, said mouse exhibiting hyperinnervation when 
compared to a normal mouse, and said gene having been 
introduced into fertilized mouse embryo of said mouse or an 
ancestor of said mouse by microinjection, and wherein said 
gene is introduced into said mouse as plasmid kl4-NGF 
hGH, deposited as of ATCC Accession. 
2. The mouse of claim 1, wherein said mouse is fertile and 
capable of transmitting said gene to its oifspring. 
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3. The mouse of claim 1, wherein said plasmid k14-NGF 
hGH comprises a 1.8 kbp sequence encoding the human 
growth hormone gene. 
4. The mouse of claim 1, wherein said mouse has a 
phenotype characterized by hyperinnervation of the skin, 
hypertrophy of the trigeminal ganglion and enlargement of 
the superior cervical sympathetic and dorsal root ganglia 
when compared to a normal mouse. 
5. A method of producing the mouse of claim 1, which 
comprises: 
18 
(a) providing a mouse nerve growth factor gene plasmid 
kl4-NGF-hGH, deposited as of ATCC Accession No. 
69423; 
(b) introducing said gene into a fertilized mouse embryo 
by microinjection; 
(c) transplanting said embryo into a pseudopregnant 
mouse; and 
(d) allowing said embryo to develop to term. 
* * * * * 
